Investigational Drug Information for Velusetrag

What is the development status for investigational drug Velusetrag?

Velusetrag is an investigational drug.

There have been 4 clinical trials for Velusetrag. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1^st 2014.

The most common disease conditions in clinical trials are Gastroparesis, Intestinal Pseudo-Obstruction, and Alzheimer Disease. The leading clinical trial sponsors are Alfasigma S.p.A., Theravance Biopharma, and Theravance Biopharma R & D, Inc.

Summary for Velusetrag

US Patents	0
International Patents	0
US Patent Applications	75
WIPO Patent Applications	23
Japanese Patent Applications	14
Clinical Trial Progress	Phase 2 (2014-12-01)
Vendors	23

Recent Clinical Trials for Velusetrag

Title	Sponsor	Phase
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).	Alfasigma S.p.A.	Phase 2
The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study	Alfa Wassermann S.p.A.	Phase 2
The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study	Alfasigma S.p.A.	Phase 2

See all Velusetrag clinical trials

Clinical Trial Summary for Velusetrag

Top disease conditions for Velusetrag

Top clinical trial sponsors for Velusetrag

See all Velusetrag clinical trials

US Patents for Velusetrag

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Velusetrag Development Update and Market Projection: TD-5108 Status, Patents, and Commercial Outlook

Last updated: September 7, 2026

Velusetrag, also known as TD-5108, is an investigational, selective 5-HT4 receptor agonist developed primarily by Theravance Biopharma for gastrointestinal motility disorders. Its main clinical targets were diabetic gastroparesis, idiopathic gastroparesis, and chronic constipation. Public development activity has not advanced to FDA submission or commercial launch. No approved velusetrag product, Orange Book listing, marketed formulation, or active biosimilar pathway exists.

The commercial base-case forecast is therefore zero product revenue unless a company revives the program, completes additional clinical development, and obtains regulatory approval. Velusetrag retains potential value as a differentiated prokinetic asset, but its risk-adjusted value is constrained by the absence of recent late-stage development, uncertain symptom efficacy, competition from existing and pipeline gastrointestinal therapies, and an unestablished patent position in marketed-product protection.

What is the current development status of velusetrag?

Velusetrag is a clinical-stage gastrointestinal motility drug candidate, not an approved medicine.

Theravance developed velusetrag as a highly selective 5-HT4 agonist intended to stimulate gastrointestinal motility without the cardiac safety liabilities associated with older serotonergic prokinetics. The program entered human studies in the late 2000s and progressed into Phase 2 studies in gastroparesis and constipation-related indications.

Item	Status
Generic name	Velusetrag
Development code	TD-5108
Drug class	Selective 5-HT4 receptor agonist
Primary developer	Theravance, later Theravance Biopharma
Main indications studied	Diabetic gastroparesis, idiopathic gastroparesis, chronic constipation
FDA approval	None identified
Commercial launch	None identified
FDA Orange Book listing	None identified
New Drug Application	No publicly identified approval filing
Biosimilar relevance	Not applicable; velusetrag is a small molecule
Current development posture	No publicly established active late-stage program

Early clinical work showed pharmacodynamic activity, including effects on gastric emptying and intestinal transit. The central development issue was whether improved motility translated into consistent, clinically meaningful reductions in gastroparesis symptoms. That distinction is important because FDA approval in gastroparesis generally requires more than a measurable gastric-emptying effect.

What clinical trials tested velusetrag?

Velusetrag was evaluated in early and mid-stage clinical studies involving healthy volunteers, patients with chronic constipation, and patients with gastroparesis.

Gastroparesis studies

Clinical studies examined velusetrag in diabetic and idiopathic gastroparesis. Endpoints included gastric emptying, symptom scores, and safety. Available public records indicate that velusetrag affected gastric motility, but the program did not produce a clearly established late-stage efficacy package supporting regulatory review.

The principal clinical risks were:

1. Gastric-emptying improvement may not correlate reliably with symptom relief.
2. Gastroparesis is a heterogeneous disease with diabetic, postsurgical, idiopathic, and medication-related causes.
3. The placebo response in symptom-driven gastrointestinal trials can be substantial.
4. Prokinetic class development requires sustained safety data because treatment may be chronic.

Chronic constipation studies

Velusetrag also showed activity in intestinal transit and bowel-movement endpoints in early studies. Chronic constipation is commercially attractive because it has a larger diagnosed and treated population than gastroparesis. It is also crowded, with marketed osmotic agents, stimulant laxatives, secretagogues, opioid antagonists, and 5-HT4 products.

The strongest commercial rationale for velusetrag would have required a clear advantage in one of four areas: faster onset, superior symptom relief, once-daily dosing, improved tolerability, or efficacy in patients inadequately controlled by existing agents.

When does velusetrag lose exclusivity?

Velusetrag has no approved-product exclusivity period because it has not received FDA approval.

Patent expiry cannot be treated as a single definitive date without identifying the relevant compound, formulation, method-of-use, and jurisdictional patent families. Public development materials identify velusetrag with Theravance patent activity, but no FDA-approved label or Orange Book patent listing establishes a marketed-product protection period.

Exclusivity category	Velusetrag position
New chemical entity exclusivity	Not granted
Orphan-drug exclusivity	No publicly identified grant
Pediatric exclusivity	None identified
FDA Orange Book patents	None identified
Approved formulation patent	None identified
Approved method-of-use patent	None identified
Regulatory exclusivity expiry	Not applicable
Commercial generic entry date	No fixed date because no reference product is approved

A future sponsor would need to assess remaining patent term family by family. Relevant questions would include whether compound claims remain enforceable, whether patent term adjustment or extension is available, whether continuation claims cover the intended indication, and whether any formulation or manufacturing claims survive prior-art challenges.

What patents protect velusetrag?

The velusetrag intellectual-property position is expected to include compound, pharmaceutical composition, and therapeutic-use claims associated with Theravance's 5-HT4 research program. Public patent databases contain Theravance filings covering 5-HT4 agonist chemistry and gastrointestinal uses, but the existence of a patent family does not establish that claims remain in force or cover a future commercial formulation.

Patent categories relevant to a velusetrag relaunch

Patent category	Potential commercial relevance
Composition-of-matter claims	Core protection for the TD-5108 molecule
Salt, polymorph, or crystalline-form claims	Could protect a selected drug substance form
Pharmaceutical-composition claims	Could cover tablets, capsules, or other dosage forms
Method-of-use claims	Could cover gastroparesis, constipation, or transit disorders
Dosing-regimen claims	Could protect dose, titration, or treatment duration
Manufacturing claims	Could create process barriers if difficult to design around
Combination claims	Could cover use with other gastrointestinal agents

The patent estate should be considered moderate rather than strong from a present commercial perspective. Compound patents can provide meaningful protection, but their value declines when a program has not reached approval and no current sponsor is visibly advancing the asset. Method-of-use patents may be narrower and more vulnerable to non-infringing prescribing or label design-around strategies.

What is the FDA regulatory status of velusetrag?

Velusetrag is not FDA-approved and is not listed in the FDA Orange Book as a reference-listed drug.

There is no publicly established FDA label, approved dosage, approved indication, risk-management program, or postmarketing safety database for velusetrag. A future sponsor would likely need to conduct additional clinical work and submit a new drug application rather than rely on an abbreviated new drug application pathway.

Because velusetrag is a small molecule without an approved reference product, a conventional generic cannot launch through the standard ANDA route. A competitor would likely need to pursue an independent 505(b)(1) application or another legally available pathway supported by its own clinical and nonclinical package.

Which companies are challenging velusetrag?

No publicly identified company has launched a Paragraph IV patent challenge against velusetrag.

That outcome is expected because Paragraph IV litigation generally follows an ANDA filing against an approved reference drug. Velusetrag has no approved reference product, no Orange Book patent listing, and no recognized generic launch pathway.

No biosimilar challenge is relevant. Biosimilar litigation applies to biologic products, while velusetrag is a synthetic small molecule.

Litigation status

Litigation issue	Current public position
Paragraph IV certification	None identified
ANDA litigation	None identified
Hatch-Waxman case	None identified
Biosimilar litigation	Not applicable
FDA patent-listing dispute	None identified
License dispute affecting launch	None publicly established

What formulations are protected by velusetrag patents?

No FDA-approved commercial formulation exists. Clinical development appears to have relied primarily on oral solid dosage forms, consistent with the pharmacology and intended chronic-use indications.

Potential formulation protection would likely involve:

• Immediate-release oral tablets or capsules
• Specific dose strengths
• Salt or polymorph forms
• Excipients affecting dissolution or stability
• Once-daily administration
• Formulations designed for predictable exposure in patients with delayed gastric emptying

A formulation patent would have limited value if a competitor could use the same active ingredient in a different, non-infringing formulation. Conversely, a strong composition-of-matter claim would provide broader protection than a tablet or dosing-regimen claim.

How strong is the velusetrag patent estate?

The estate has historical value but limited current commercial certainty.

Strengths

• Selective 5-HT4 pharmacology addresses a recognized gastrointestinal motility mechanism.
• Composition-of-matter protection may have been available from early development filings.
• Gastroparesis and chronic constipation provide multiple potential indications.
• The absence of an approved product eliminates immediate generic competition.

Weaknesses

• No FDA-approved product creates no regulatory moat.
• No Orange Book listing provides no current Hatch-Waxman enforcement position.
• Clinical development has not established a commercial label.
• Method-of-use claims may be narrow.
• A revived program would face new clinical, manufacturing, and regulatory costs.
• Older patent families may have limited remaining term depending on filing and priority dates.

The key valuation question is not whether historical patents existed. It is whether enforceable claims remain available for the indication, formulation, and dosing regimen that a future sponsor would commercialize.

How does velusetrag compare with competing gastrointestinal drugs?

Velusetrag would enter markets with established symptomatic treatments and competing prokinetic approaches.

Product or class	Main use	Commercial position relative to velusetrag
Metoclopramide	Gastroparesis	FDA-approved in the United States; safety limitations constrain chronic use
Domperidone	Gastroparesis	Used under restricted access in the United States; broader availability in some markets
Prucalopride	Chronic constipation	Approved 5-HT4 agonist with established class validation
Linaclotide	IBS-C and chronic idiopathic constipation	Strong branded and guideline presence
Plecanatide	IBS-C and chronic idiopathic constipation	Competes through secretagogue mechanism
Lubiprostone	Chronic idiopathic constipation and IBS-C	Established oral treatment
Relamorelin	Gastroparesis development	Competing prokinetic mechanism, depending on development status
Tradipitant	Gastroparesis development	Symptom-focused, particularly nausea, depending on regulatory progress

Velusetrag's differentiation would need to come from efficacy in gastroparesis symptoms, rather than gastric-emptying data alone. In chronic constipation, the drug would need to compete against established 5-HT4 and secretagogue products with commercial reimbursement infrastructure.

What market size and revenue can velusetrag achieve?

The current approved-product revenue forecast is zero because velusetrag is not marketed.

A future commercial forecast should be scenario-based rather than treated as a conventional launch forecast.

Scenario	Development assumption	Commercial outcome
Base case	No renewed sponsor or clinical program	$0 revenue
Revival case	New sponsor conducts Phase 2 and selects one indication	Limited value creation before proof of efficacy
Approval case	Positive late-stage trial and FDA approval in gastroparesis	Specialty-gastroenterology product with targeted uptake
Dual-indication case	Approval in gastroparesis and constipation	Larger addressable market, but heavier competition
Premium differentiation case	Superior symptom efficacy and tolerability	Potential for meaningful branded pricing and licensing value

The addressable patient population is large, but the treatable and reimbursed market is smaller. Many patients with constipation use low-cost generics or over-the-counter products. Gastroparesis has greater unmet need, but diagnosis is difficult, treatment is fragmented, and reimbursement can be restrictive.

A reasonable investment conclusion is that velusetrag's near-term market value is option value, not product revenue. The asset could attract licensing interest if new data demonstrated symptom improvement, clean cardiovascular safety, and a practical oral dosing profile. Without those data, a material revenue forecast is unsupported.

What licensing deals affect velusetrag?

Theravance has historically used licensing and collaboration structures across its pipeline, but no current publicly established licensing transaction has produced a marketed velusetrag product. No active commercial partner with a disclosed launch plan has been identified.

A future transaction would likely be structured around clinical milestones:

1. Upfront payment at licensing.
2. Development and regulatory milestones.
3. Commercial milestones tied to approval or sales.
4. Tiered royalties.
5. Regional rights for the United States, Europe, Japan, or emerging markets.

The absence of a visible active partner reduces the probability of near-term development and makes any valuation dependent on the cost of reactivation.

What generic launch risks exist for velusetrag?

There is no immediate generic launch risk because no reference product is approved.

If velusetrag were approved, potential challenges would include:

• ANDA filing after Orange Book listing
• Paragraph IV certification
• Attacks on compound-patent validity
• Non-infringement arguments involving method-of-use claims
• Alternative salt, polymorph, or formulation development
• Patent-term expiration before commercial uptake
• Off-label use that weakens the practical value of method-of-use claims

A future generic could be delayed by strong composition-of-matter protection, but no current Orange Book record creates no present litigation barrier.

What is the geographic coverage of velusetrag rights?

Velusetrag's clinical development was centered on the United States, with international clinical and patent activity potentially relevant to Europe and other major pharmaceutical markets. Geographic patent value depends on national validation, maintenance payments, claim scope, and remaining term.

A global commercialization strategy would require separate review of:

• United States composition and use patents
• European Patent Convention validations
• Japan and other major Asian markets
• Regulatory data exclusivity outside the United States
• Local patent term adjustment rules
• Manufacturing and supply-chain rights
• Regional licensing restrictions

No current country has an approved velusetrag product with an established exclusivity timetable.

Key Takeaways

• Velusetrag, or TD-5108, is an investigational selective 5-HT4 agonist associated primarily with Theravance.
• The drug was studied for gastroparesis and chronic constipation.
• No FDA approval, Orange Book listing, commercial launch, or active generic challenge has been identified.
• The current product-revenue forecast is zero.
• Future value depends on program revival, new clinical evidence, and confirmation of surviving patent protection.
• The main clinical hurdle is demonstrating symptom relief, not only faster gastric emptying.
• Prucalopride, metoclopramide, secretagogues, and emerging gastroparesis therapies create substantial competitive pressure.
• Velusetrag is a licensing option with uncertain development value, not an active commercial asset.

FAQs about velusetrag

Is velusetrag approved for gastroparesis?

No. Velusetrag has not received FDA approval for gastroparesis or another indication.

Is velusetrag the same drug as prucalopride?

No. Both are selective 5-HT4 agonists, but they are different molecules developed by different companies.

Can a generic company launch velusetrag now?

No conventional generic launch is available because velusetrag has no approved reference product and no Orange Book listing.

Did velusetrag fail in clinical development?

Public development activity does not establish a formal regulatory failure determination. The program did not progress to an identified FDA approval, and no active late-stage commercial program is publicly established.

Could velusetrag still be revived?

Yes, but revival would require a sponsor to reassess patent life, manufacturing feasibility, clinical data, cardiovascular safety, and the probability of achieving symptom-based efficacy in a competitive gastrointestinal market.

References

1. ClinicalTrials.gov. (n.d.). Velusetrag clinical studies. U.S. National Library of Medicine. https://clinicaltrials.gov/

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Camilleri, M. (2015). Novel pharmacology: Asimadoline and other therapeutic options for gastrointestinal motility disorders. Neurogastroenterology & Motility, 27(2), 137-146.

4. Theravance Biopharma, Inc. (n.d.). Pipeline and product development materials. Company filings and investor publications.

5. U.S. Food and Drug Administration. (2020). Drug development and approval process for gastrointestinal motility disorders. https://www.fda.gov/